Immunocore Holdings plc Cash Flows From Used In Operations
Immunocore Holdings plc (IMCR) reported Cash Flows From Used In Operations of -GBP 3.33 million for the 6-month period ending 2023-06-30, per its 6-K filed 2023-08-10.
Discontinued › Notes
ifrs-full:CashFlowsFromUsedInOperations · last filed 2023-08-10
- Immunocore Holdings plc cash flows from used in operations for the quarter ending 2022-12-31 was 6.04M GBP.
- Immunocore Holdings plc cash flows from used in operations for the quarter ending 2022-09-30 was 8.71M GBP.
- Immunocore Holdings plc cash flows from used in operations for the quarter ending 2021-12-31 was -28.72M GBP.
| Period end | Cash Flows From Used In Operations 3 month | Cash Flows From Used In Operations 6 month | Cash Flows From Used In Operations 9 month | Cash Flows From Used In Operations 12 month |
|---|---|---|---|---|
| 2023-06-30 | -3.33M GBP 6-K · filed 2023-08-10 | |||
| 2022-12-31 | 6.04M GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | 14.74M GBP derived: sum of 2 quarters · filed 2023-03-01 | -25.27M GBP 20-F · filed 2023-03-01 | |
| 2022-09-30 | 8.71M GBP derived: 6-K/A 9 month − 6-K 6 month · filed 2022-11-18 | -31.31M GBP 6-K/A · filed 2022-11-18 | ||
| 2022-06-30 | -40.02M GBP 6-K · filed 2023-08-10 | |||
| 2021-12-31 | -28.72M GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | -108.49M GBP 20-F · filed 2023-03-01 | ||
| 2021-09-30 | -79.78M GBP 6-K/A · filed 2022-11-18 | |||
| 2020-12-31 | -101.55M GBP 20-F · filed 2023-03-01 | |||
| 2019-12-31 | -116.38M GBP 20-F · filed 2022-03-03 | |||
| 2018-12-31 | -17.32M GBP 20-F · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |